Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 7, 2003, Pages 787-795

  Suzuki, Hidekazu ^a   Miyazawa, Masaharu ^a   Nagahashi, Shoichi ^a   Sato, Masaru ^b   Bessho, Motoaki ^b   Nagata, Hiroshi ^a   Miura, Soichiro ^c   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

^b EISAI CO LTD   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Antioxidant; Gastritis; Helicobacter pylori; Leukocyte; Oxygen radical; Proton pump inhibitor

Indexed keywords

GLUTATHIONE; RABEPRAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EVALUATION; GERBIL; HELICOBACTER PYLORI; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; INJECTION; INOCULATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; STOMACH MUCOSA LESION;

EID: 0042703459     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03038.x     Document Type: Article

References (23)

1. Suzuki H, Mori M, Seto K et al. H. pylori-associated gastric pro- and anti-oxidant formation in Mongolian gerbils. Free Radic. Biol. Med. 1999; 26: 679-84.
2. Tsuchiya M, Imamura L, Park J-B, Kobayashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol. Pharm. Bull. 1995; 18: 1053-6.
3. Park JB, Imamura L, Kobayashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol. Pharm. Bull. 1996; 19: 182-7.
4. Tsutsui N, Taneike I, Ohara T et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44: 3069-73.
5. Fujisaki H, Shibata H, Oketani K et al. Inhibition of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem. Pharmacol. 1991; 42: 321-8.
6. Hirayama F, Takagi S, Kusuhara H, Iwao E, Yokoyama Y, Ikeda Y. Induction of gastric ulcer and intestinal metaplasia in Mongolian gerbils infected with Helicobacter pylori. J. Gastroenterol. 1996; 31: 755-7.
7. Takahashi S, Keto Y, Fujita H, Muramatsu H, Nishino T, Okabe S. Pathological changes in the formation of Helicobacter pylori induced gastric lesions in Mongolian gerbils. Dig. Dis. Sci. 1998; 43: 754-65.
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265-75.
9. Smith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Annal Biochem. 1985; 150: 76-85.
10. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. Am. J. Surg. Pathol. 1996; 20: 1161-81.
11. Misiewicz JJ, Tytgat GNJ, Goodwin CS, Price AB, Sipponen P, Strickland RG. The Sydney Systems: a new classification of gastritis. Working Party Reports of the World Congress of Gastroenterology 1990: 1-12.
12. Price AB. The Sydney system. Histological division. J. Gastroenterol. Hepatol. 1991; 6: 209-22.
13. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am. J. Physiol. 1986; 252: G567-74.
14. Jonas CR, Estivariz CF, Jones DP et al. Keratinocyte growth factor enhances glutathione redox state in rat intestinal mucosa during nutritional repletion. J. Nutr. 1999; 127: 1278-84.
15. Yasuda S, Higashi S, Murakami M, Tomono Y, Kawaguchi M. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 1999; 37: 249-53.
16. Bamba H, Kondo Y, Wong RM, Sekine S, Matsuzaki F. Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Am. J. Gastroenterol. 1997; 92: 659-62.
17. Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori, unique action selective for H. priori cells. Antimicrob. Agents Chemother. 1993; 37: 769-74.
18. Josenhans C, Labigne A, Suerbaum S. Comparative ultrastruetural and functional studies of Helicobacter pylori and Helicobacter mustelae flagellin mutants: both flagellin subunits, FlaA and FlaB, are necessary for full motility in Helicobacter species. J. Bacteriol. 1995; 177: 3010-20.
19. Suzuki H, Mori M, Seto K et al. Polaprezinc attenuates the H. pylori-induced gastric mucosal leukocyte activation in Mongolian gerbils: a study using intravital videomicroscopy. Aliment Pharmacol. Ther. 2001; 15: 715-25.
20. Ohara T, Goshi S, Taneike T, Tamura Y, Zhang H-M, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin resistant Helicobacter pylori. Helicobacter 2001; 6: 125-9.
21. Yoshida N, Yoshikawa T, Tanaka Y et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol. Ther. 2000; 14 (Suppl. 1): 74-81.
22. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33: 617-21.
23. Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996; 382: 189-92.